Later-Line KRAS-Targeted Treatments Available in Lung Cancer

Analyses Probe into Co-Mutation Activity of Sotorasib in KRAS-Mutant NSCLC

KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC

During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.

Randomized Trial Provides Biomarker and CNS Sotorasib Data in NSCLC

During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the results of the phase 3 CodeBreaK 200 trial in patients with KRAS G12C-positive lung cancer. This is the second article based on this event.

Identifying the Role of Targeted Therapy in KRAS-Mutated NSCLC

During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the use of sotorasib and adagrasib for patients with KRAS-mutated non–small cell lung cancer including those with brain metastases.